Use of antisense oligonucleotides to inhibit the expression of Akt-1

Details for Australian Patent Application No. 2003258183 (hide)

Owner Rexahn Pharmaceuticals, Inc.

Inventors Lee, Young Bok; Yoon, Heejeong; Ahn, Chang Ho; Mao, Lingjun

Agent Davies Collison Cave

Pub. Number AU-B-2003258183

PCT Number PCT/US03/25250

PCT Pub. Number WO2004/016215

Priority 60/404,010 16.08.02 US

Filing date 13 August 2003

Wipo publication date 3 March 2004

Acceptance publication date 26 March 2009

International Classifications

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

C07H 21/04 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Event Publications

13 November 2003 Complete Application Filed

  Priority application(s): 60/404,010 16.08.02 US

22 April 2004 Application Open to Public Inspection

  Published as AU-B-2003258183

26 February 2009 Assignment before Grant

  Rexahn Corporation The application has been assigned to Rexahn Pharmaceuticals, Inc. 2004

26 March 2009 Application Accepted

  Published as AU-B-2003258183

23 July 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003258184-SESSION KEY MANAGEMENT FOR PUBLIC WIRELESS LAN SUPPORITNG MULTIPLE VIRTUAL OPERATORS

2003258182-VAPOR DISPENSING DEVICE HAVING IMPROVED TRANSVERSE LOADING STABILITY